

FORM 7

MONTHLY PROGRESS REPORT

Name of CNSX Issuer: Cannabix Technologies Inc. (the "Issuer").

Trading Symbol: BLO

Number of Outstanding Listed Securities: 122,842,766 common shares

Date: for June 5, 2026

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by the CNSX Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the CNSX.ca website.

This report is intended to keep investors and the market informed of the Issuer's ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the CNSX Policies. The discussion in this report must be factual, balanced and non-promotional. *See cautionary note on forward looking statements at the end of this report.

General Instructions

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term "Issuer" includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

The issuer, "Cannabix Technologies Inc.", or "Cannabix", or "the Company" is developing marijuana breathalyzer devices for various markets including law enforcement and employers. The Company also has wall mounted alcohol breath screening devices. All products are at the prototype development stage.

Cannabix Technologies is developing new technologies to collect and help detect Tetrahydrocannabinol (known as “THC”- the psychoactive component of marijuana) in human breath samples for law enforcement and employers and a host of other settings (Cannabix Marijuana Breath Test). Cannabix has also developed unmanned wall mounted alcohol screening devices for a range of applications (BreathLogix product line). Cannabix has filed its own provisional and non-provisional patent applications in relation to various aspects of its intellectual property and are under review by US and Canadian and other international patent offices. The Company’s intellectual property stems from its ongoing research and development activities.

The Company has been granted US Patent 14,689,434 entitled, “Cannabis Drug Detection Device.”

The Company has been granted patent 2887841 entitled, “*Cannabis Drug Detection Device*” from the Canadian Intellectual Property Office.

The Company has been granted US patent 17/019728 entitled, “*Apparatus and Methods for Detection of Molecules*”.

The Company has been granted US patent 18/1729,658 entitled, “*Contact-Free Breath Analysis Device and Method*”.

The Company has licensed US Patent 8,237,118 (field of use is the exclusive worldwide rights in breath analysis of controlled substances) from the University of Florida.

Technology

The Cannabix Marijuana Breath Test (MBT) is a laboratory-based *collect and send* drug screening/confirmation solution targeted for employers, laboratories and law enforcement. The MBT consists of portable sample breath collection, confirmed via laboratory-based analysis (by Omega Laboratories) focused on “recent use” detection of delta-9 THC. Cannabix is developing its Breath Collection Unit (BCU), Breath Cartridge (BC) when used together, helps complete human breath sample collection, transport and storage. The sample analysis stage is completed using Omega’s laboratory-based liquid chromatography–mass spectrometry (LC–MS) test method. See “Strategic Partnership with Omega Laboratories” below.

BreathLogix –Alcohol Breathalyzer Devices

BreathLogix rapidly checks for breath alcohol and simultaneously takes a photo of the user to confirm and record identity. The device delivers precise Blood Alcohol Content (BAC) levels on the screen and sends real-time test reports via SMS and e-mail, alerting managers to positive BAC results so they can take immediate action to avoid damage and injury. All test results can be logged and managed on a dedicated ‘Connect’ web portal. BreathLogix can be integrated with doors, turnstiles, gates, facial recognition, fingerprint readers and motor vehicle key fleet management systems for pre-access alcohol testing. Furthermore, the device can be used for start-of-shift testing, mandated testing, pre-employment testing, return-to-work testing, random and post-incident testing.

BreathLogix includes patent pending pre-calibrated sensor cartridge technology allowing administrators to easily maintain their devices, in addition, BreathLogix's *Contact-Free Breath Analysis Method* has been granted notice of allowance by CIPO and USPTO to date.

MS Breath Sampler (MSBS)

The MSBS is specialized laboratory hardware developed by Cannabix to help confirm THC in breath from humans. The MSBS is mounted (coupled) to a mass spectrometer and sample is analyzed using existing MS/MS methods with no sample preparation needed.

The MSBS is a novel method for efficient collection of analytes of low volatility from human breath utilizing liquid secondary adsorption. The concept has demonstrated efficient capturing and releasing of THC. This novel method uses breath aerosols as a carrier of solid and viscous liquid particle analytes as well as a secondary adsorbent to prevent sample loss from droplet surface contact and deposition. Cannabix scientists observe that the collection efficiency of MSBS sampling method is effective for THC analyte detection. Using the Cannabix method the results for a breath sample can be acquired from start to finish within a few minutes without any sample preparation or preconcentration steps.

Breath samples are collected portably with a Breath Collection Unit (BCU). Within the BCU, the sample is captured inside a cartridge (the Cannabix BC) and loaded into the MSBS for mass spec (MS) laboratory analysis.

Strategic Partnership with Omega Laboratories

Cannabix and Omega Laboratories entered into a strategic partnership and development agreement (2024) to work together to commercial the Company's BCU and breath cartridge technology. The agreement between Omega and Cannabix works to advance Cannabix's technology from the research and development stage to commercialization.

Omega Laboratories is an international industry leader in forensic drugs of abuse testing. Omega has multiple federal as well as international certifications and accreditations.

Pursuant to the Agreement, Cannabix and Omega Laboratories have agreed to, among other things, complete research and development, refine and expand the use of Cannabix's technology to meet existing and emerging needs of Omega's clients and industry, contemplate manufacturing and distribution and introduce the delta9 THC breath testing technology to customers in North America.

FAIMS technology

The Company is developing technology to detect THC in breath using *high-field asymmetric waveform ion mobility spectrometry* known as "FAIMS" and FAIMS-mass spectrometer systems (FAIMS-MS).

FAIMS is specialized ion filtering technology centered on a "FAIMS cell" and specialized electronics. The Company has invested resources to characterize its FAIMS

cell and supporting electronics to help establish repeatable results, improve resolving power and separation capability – additional characterization work is needed. The Company has also invested resources to develop a novel “detector” technology that would confirm specific ions (like THC) that have been filtered through the FAIMS cell, delivering a confirmation signal. The characterization work is conducted using a bench version instrumentation. Additional R&D is required for this instrument and all supporting electronics and hardware are at the prototype development stage.

2. Provide a general overview and discussion of the activities of management.

During the month the Company worked to advance its Cannabix Marijuana Breath (“MBT”) Test and BreathLogix (Alcohol) technologies. During the month the Company worked on business development and technology servicing and development efforts for its BreathLogix technology and Marijuana Breath (“MBT”) Test solution. During the month the Company worked on its commercial phased rollout of the Marijuana Breath Test (“MBT”) system. The phased commercialization strategy is designed to manage operational risk, refine product performance in real-world settings, and build a scalable sales and distribution framework. Initial market entry is expected to involve early deployment with a select group of early-adopter customers. This phased rollout is intended to allow the Company to validate workflows, integration requirements, reliability, and customer use patterns, while gathering feedback to inform product pricing and refinement, and support materials. During the early stages of commercialization, the Company anticipates working primarily with third-party resellers/distributors, and strategic partners to access target markets. The reseller-based approach is expected to provide flexibility and market reach while Cannabix continues to evaluate demand, pricing strategies, and customer adoption dynamics. Furthermore, during the month, the Marijuana Breath Test (“MBT”) products were sold to a drug and alcohol testing clinic serving workplace clients in eastern Canada and its BreathLogix alcohol screening technology were deployed with mining, municipal, and aviation clients in Australia (via Australian based exclusive distribution partner, Breathalyser Sales & Service Pty Ltd.) further penetrating high-value safety-critical sectors, seeking automated alcohol screening technology. The Company also achieved Underwriters Laboratories (UL) and Canadian Standards Association (CSA) electrical safety certifications for its portable Breath Collection Unit (BCU), a core component of the Company’s Marijuana Breath Test (MBT).

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

There were no products or services added during the month.

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

There were no products or services discontinued during the month.

5. Describe any new business relationships entered into between the Issuer, the Issuer’s affiliates or third parties including contracts to

supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

See item 2.

Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

None to report.

6. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

None to report.

7. Describe the acquisition of new customers or loss of customers.

See item 2.

8. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

None to report.

9. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

None to report.

10. Report on any labour disputes and resolutions of those disputes if applicable.

None to report.

11. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

None to report.

12. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

There was no new indebtedness incurred or repaid by the Issuer during the month.

13. Provide details of any securities issued and options or warrants granted.

During the month the following common shares were issued/cancelled the following:

| Type | Details |
|------|---------|
| Nil | Nil |

14. Provide details of any loans to or by Related Persons.

There were no new loans to, or by, Related Persons during the month.

15. Provide details of any changes in directors, officers or committee members.

There were no changes in directors, officers or committee members, during the month.

16. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

None to report.

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to CNSX that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all CNSX Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated June 5, 2026 _____.

Rav Mlait
Name of Director or Senior Officer
(signed) "Rav Mlait"
Signature

Chief Executive Officer
Official Capacity

| | | | |
|---------------------------------|--|--------------------------|-----------------------|
| Issuer Details | | For Month End | Date of Report |
| Name of Issuer | | May | YY/MM/DD |
| Cannabix Technologies Inc. | | | 2026/06/05 |
| Registered Address | | | |
| 501 - 3292 Production Way | | | |
| City/Province/Postal Code | | Issuer Fax No. | Issuer Telephone No. |
| Burnaby, BC, V5A 4R4 | | N/A | 604-551- 7 8 31 |
| Contact Name | | Contact Position | Contact Telephone No. |
| Rav Mlait | | CEO | 604-551- 7 8 31 |
| Contact Email Address | | Web Site Address | |
| info@ cannabixtechnologies. com | | cannabixtechnologies.com | |

*Cautionary Statement Regarding Forward-Looking Statements

This document contains certain “forward-looking statements” and “forward-looking information” within the meaning of applicable Canadian securities laws (collectively, “forward-looking statements”). All statements in this release that are not purely historical in nature should be considered forward-looking statements, including, without limitation, statements regarding: the Company’s plans for the commercial rollout of the Company’s products, including the MBT system and BreathLogix; anticipated customer adoption and market demand; expectations related to manufacturing scale-up, recurring revenue streams, and operational processes; potential technological developments or enhancements; future partnerships or commercial agreements; regulatory approvals; and the Company’s ability to complete future financings or achieve other business milestones. Forward-looking statements are often identified by terminology such as “anticipate,” “believe,” “continue,” “estimate,” “expect,” “goal,” “intend,” “may,” “plan,” “potential,” “project,” “proposed,” “target,” “will,” and similar expressions, or statements that events or conditions “may” or “will” occur. These statements are based on the beliefs, assumptions, and expectations of management in light of currently available information. Forward-looking statements involve known and unknown risks, uncertainties, and other factors—many of which are beyond the Company’s control—that may cause actual results, performance, or achievements to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to: adverse market conditions; the Company’s ability to successfully manufacture, deploy, and commercialize the MBT system or any other current or future products; risks associated with regulatory approvals and evolving legal frameworks for cannabis testing; reliance on third-party laboratory and manufacturing partners; the protection and enforceability of intellectual property rights; technological uncertainties; competition; potential delays in product development or customer adoption; risks related to future financings; and the possibility that strategic partnerships may not advance as expected or may not be completed at all. Readers are cautioned that undue reliance should not be placed on forward-looking statements. Actual results and future events may differ materially from those expressed or implied by such statements. Forward-looking statements in this release are provided as of the date hereof, and the Company undertakes no obligation to update or revise any forward-looking statements except as required under applicable securities laws.